Pfizer

Small is better for vaccine shares - THE EDGE SINGAPORE

Covid-19

Small is better for vaccine shares

Big vaccine news makes little difference to pharma giant shares.
BOS sees clear skies over markets following US elections  - THE EDGE SINGAPORE

Broker's Calls

BOS sees clear skies over markets following US elections

Despite some market turbulence ahead, Lee calls on investors to fix their eyes on an impending economic re-opening.
Analysts mixed on SATS despite potential Covid-19 vaccine, air travel bubble - THE EDGE SINGAPORE

Broker's Calls

Analysts mixed on SATS despite potential Covid-19 vaccine, air travel bubble

DBS Group Research reckons that a recovery to pre-Covid-19 levels for international air travel could occur in 2022.
STI continues upward trajectory on better results, vaccine optimism - THE EDGE SINGAPORE

STI watch

STI continues upward trajectory on better results, vaccine optimism

The benchmark Straits Times Index (STI) rose 34.69 points or 1.28% as at 12.58pm to 2,746.08.
SIA gets a lift from potential Covid vaccine and travel bubble but recovery still nascent - THE EDGE SINGAPORE

Company in the news

SIA gets a lift from potential Covid vaccine and travel bubble but recovery still nascent

SIA says it is encouraged by the development of Pfizer’s experimental Covid-19 vaccine.

Company in the news

SATS able to transport Pfizer’s experimental Covid-19 vaccine at low temperatures: CEO

“We are certified to handle at that temperature,” says SATS CEO Alex Hungate.
DBS Research bets Covid-19 recovery hopes on Covid-19 vaccine in 2021 - THE EDGE SINGAPORE

Broker's Calls

DBS Research bets Covid-19 recovery hopes on Covid-19 vaccine in 2021

Ten of the candidates are now in Phase 3 trials, with the first results coming out as soon as October.

Global review

China could well be the winner of the Covid-19 vaccine race

The race is on for the first Covid-19 vaccine, with five Chinese companies among the 10 that are in phase III studies.

Covid-19

Is a viable Covid-19 vaccine imminent?

Dr Mike Ryan, head of WHO’s emergencies program maintains that there is still a long way to go before a vaccine can be rolled out.
×